Cyclerion Therapeutics, Inc.

Equities

CYCN

US23255M2044

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.93 ^USD	-3.62%		-16.29%	-12.54%

Mar. 05	Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Cyclerion Therapeutics, Inc. Appoints Regina Graul as President	CI

Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 05, 2024 at 04:16 pm EST

Cyclerion Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 5.26 million compared to USD 44.08 million a year ago. Basic loss per share from continuing operations was USD 5.39 compared to USD 8.4 a year ago.

Basic loss per share was USD 2.25 compared to USD 20.28 a year ago.

Latest news about Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
Cyclerion Therapeutics, Inc. Appoints Regina Graul as President	Dec. 04	CI
Cyclerion Therapeutics, Inc. Announces Board of Directors Appointments	Nov. 30	CI
Cyclerion Therapeutics, Inc. Announces Resignation of Ole Isacson as Director	Nov. 24	CI
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Cyclerion Therapeutics, Inc. Announces Anjeza Gjino Resigns as Chief Financial Officer	23-10-23	CI
Cyclerion Therapeutics Acquires 10% Stake in Tisento Therapeutics in Asset Purchase Deal	23-07-31	MT
Tisento Therapeutics, Inc. announced that it has received $81 million in funding from Cyclerion Therapeutics, Inc., Invus, Polaris, and other investors	23-07-30	CI
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-28	CI
Cyclerion Therapeutics, Inc. Announces Resignation of Cheryl Gault as Chief Operating Officer	23-06-27	CI
Cyclerion Therapeutics, Inc. announced that it has received $5.000001 million in funding	23-05-24	CI
Cyclerion Therapeutics to Implement 1-for-20 Reverse Stock Split	23-05-15	MT
Cyclerion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Cyclerion Therapeutics to Sell Zagociguat, CY3018 Assets to New Private Company	23-05-12	MT
J & W Cycles, Inc. signed a definitive agreement to acquire sGC Stimulator Assets of Cyclerion Therapeutics, Inc. for $8 million.	23-05-10	CI
Cyclerion in Talks on Buyout Proposal for Drug Assets; CEO Offers to Make Equity Investment	23-04-03	MT
Cyclerion Therapeutics, Inc. announced that it expects to receive $5.000001 million in funding	23-03-30	CI
Cyclerion Therapeutics Says FDA Grants Orphan Drug Designation to Zagociguat; Shares Jump	23-03-27	MT
Cyclerion Gets FDA Orphan Designation for Zagociguat in Mitochondrial Diseases	23-03-27	DJ
Cyclerion Therapeutics' Zagociguat Gets FDA Orphan Drug Status	23-03-23	MT
Cyclerion Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	23-03-21	CI
North American Morning Briefing : Futures Deep in -3-	23-03-15	DJ
A group including Cyclerion Therapeutics, Inc.'s Chief Executive Officer cancelled the acquisition of Certain Assets of Cyclerion Therapeutics, Inc..	22-11-21	CI
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI
Cyclerion Therapeutics, Inc. Announces Resignation of Andreas Busch as Chief Scientific Officer	22-09-30	CI

Chart Cyclerion Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing treatments for serious diseases. The Companyâs portfolio includes novel soluble guanylate cyclase (sGC) stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. Olinciguat is a vascular sGC stimulator that the Company intends to out-license for cardiovascular diseases. The Company operates through the human therapeutics segment. The Company is focused on identifying non-sGC stimulator assets within the central nervous system (CNS) therapeutic area to build a new portfolio. The Company is also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments.

Sector

Biotechnology & Medical Research

Calendar

2024-04-30 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
CYCLERION THERAPEUTICS, INC.	-12.54%	7.44M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research